Date:8/9/2011

ntegrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.CONTACTS:

James Winschel, Senior Vice President and Chief Financial OfficerJill Baker, Corporate Vice President of Investor Relations+1-781-434-4118PAREXEL International CorporationConsolidated Condensed Statement of OperationsUnauditedThree Months EndedThree Months Ended(in thousands, except per share data)June 30, 2011June 30, 2010 (a)As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
310,524$
-$  310
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call
3. PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference
4. PAREXEL Invites Public to Listen to Live Webcast of Its Investor Day June 2, 2011
5. PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results
6. Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL
7. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
8. PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call
9. PAREXEL Experts To Address Best-Practice Strategic Partnership Models To Increase Operating Efficiency, Development Effectiveness at Partnerships in Clinical Trials
10. PAREXEL Experts to Present Advanced Approaches to Accelerate Development, Maximize Product Value at DIA EuroMeeting
11. PAREXEL International to Present at Raymond James Investors Conference